Results 251 to 260 of about 4,889,938 (291)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and the Risk of Acute Pancreatitis: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Alves C, Costa B, Penedones A, Mendes D, Batel Marques F.   +4 more
europepmc   +1 more source

Angiotensin II and TGF-β1 Induce Alterations in Human Amniotic Fluid-Derived Mesenchymal Stem Cells Leading to Cardiomyogenic Differentiation Initiation

, 2019
Monika Gasiūnienė, Gintautas Petkus, Dalius Matuzevičius, Dalius Navakauskas, Rūta Navakauskienė   +4 more
openalex   +2 more sources

Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril. [PDF]

Pharmaceutics
Steichert M, Cawello W, Burckhardt BB, Suessenbach FK, Laeer S, On Behalf Of The Lena Consortium.   +5 more
europepmc   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices

ESC Heart Failure, EarlyView.
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim, Hoang Nhat, Mahmoud Abdelnabi, Beani Forst, Mohamed Allam, Xuan Ci Mee, Ghee Kheng Lim, George Bcharah, Timothy Barry, Juan Farina, Chadi Ayoub, Reza Arsanjani, Kwan Lee   +12 more
wiley   +1 more source

Cardiomyocyte-specific LARP6 overexpression prevents angiotensin II-induced myocardial dysfunction and interstitial fibrosis. [PDF]

Am J Physiol Heart Circ Physiol
Russell JJ, Yoshida T, Ma L, Lee L, Davis DJ, Grisanti LA, Ruff M, Bailey CA, Bender SB, Chandrasekar B.   +9 more
europepmc   +1 more source

Role of agonistic autoantibodies to the angiotensin II type 1 receptor (AT1-AA) in pathogenesis of preeclampsia

Jing Wang, Shan Lang, Yanhui Zhao, Hongwen Cao, Shuhai Lan, Yizhong Yan   +5 more
openalex   +1 more source

Early in‐hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

ESC Heart Failure, EarlyView.
This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu, Andrew P. Ambrosy, Gad Cotter, Edimar A. Bocchi, Javed Butler, Ovidiu Chioncel, Beth Davison, Anastase Dzudie, Yonathan Freund, Marat Fudim, Sivadasanpillai Harikrishnan, Ivna G. Cunha, Alexandre Mebazaa, Robert J. Mentz, Òscar Miró, Siti E. Nauli, Mateo Pagnesi, Naoki Sato, Gianluigi Savarese, Karen Sliwa‐Hahnle, Yuhui Zhang, Jingmin Zhou, Jan Biegus   +22 more
wiley   +1 more source

Critical role of the β isoform of protein kinase C (PKCβ) in angiotensin II-induced oxidative stress in vascular smooth muscle cells. [PDF]

Physiol Rep
Tajima H, Naganishi S, Mukohda M, Ishida M, Hamada N, Shigemi N, Yamasaki T, Nakamura S, Matsui T, Mizuno R, Ozaki H.   +10 more
europepmc   +1 more source

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source